136 related articles for article (PubMed ID: 21108609)
21. [Major histocompatibility complex class II antigens on renal cell cancer--immunohistochemical study and effect on their expression by interferon].
Tomita Y
Nihon Hinyokika Gakkai Zasshi; 1990 Jul; 81(7):1079-86. PubMed ID: 2120500
[TBL] [Abstract][Full Text] [Related]
22. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma.
Uemura H; Fujimoto K; Tanaka M; Yoshikawa M; Hirao Y; Uejima S; Yoshikawa K; Itoh K
Clin Cancer Res; 2006 Mar; 12(6):1768-75. PubMed ID: 16551861
[TBL] [Abstract][Full Text] [Related]
23. Expression and regulation of non-classical HLA-G in renal cell carcinoma.
Dunker K; Schlaf G; Bukur J; Altermann WW; Handke D; Seliger B
Tissue Antigens; 2008 Aug; 72(2):137-48. PubMed ID: 18721274
[TBL] [Abstract][Full Text] [Related]
24. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma.
Ibrahim EC; Guerra N; Lacombe MJ; Angevin E; Chouaib S; Carosella ED; Caignard A; Paul P
Cancer Res; 2001 Sep; 61(18):6838-45. PubMed ID: 11559559
[TBL] [Abstract][Full Text] [Related]
25. Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response.
Bukur J; Malenica B; Huber C; Seliger B
Hum Immunol; 2003 Nov; 64(11):1081-92. PubMed ID: 14602239
[TBL] [Abstract][Full Text] [Related]
26. HLA-E expression and its clinical relevance in human renal cell carcinoma.
Seliger B; Jasinski-Bergner S; Quandt D; Stoehr C; Bukur J; Wach S; Legal W; Taubert H; Wullich B; Hartmann A
Oncotarget; 2016 Oct; 7(41):67360-67372. PubMed ID: 27589686
[TBL] [Abstract][Full Text] [Related]
27. Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma.
Gastl G; Ebert T; Finstad CL; Sheinfeld J; Gomahr A; Aulitzky W; Bander NH
J Urol; 1996 Jan; 155(1):361-7. PubMed ID: 7490887
[TBL] [Abstract][Full Text] [Related]
28. Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma.
Romero JM; Aptsiauri N; Vazquez F; Cozar JM; Canton J; Cabrera T; Tallada M; Garrido F; Ruiz-Cabello F
Tissue Antigens; 2006 Oct; 68(4):303-10. PubMed ID: 17026465
[TBL] [Abstract][Full Text] [Related]
29. MAGED4-expression in renal cell carcinoma and identification of an HLA-A*25-restricted MHC class I ligand from solid tumor tissue.
Krämer BF; Schoor O; Krüger T; Reichle C; Müller M; Weinschenk T; Hennenlotter J; Stenzl A; Rammensee HG; Stevanovic S
Cancer Biol Ther; 2005 Sep; 4(9):943-8. PubMed ID: 16082191
[TBL] [Abstract][Full Text] [Related]
30. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
[TBL] [Abstract][Full Text] [Related]
31. Higher HLA class I expression in renal cell carcinoma than in autologous normal tissue.
Sáenz-López P; Gouttefangeas C; Hennenlotter J; Concha A; Maleno I; Ruiz-Cabello F; Cózar JM; Tallada M; Stenzl A; Rammensee HG; Garrido F; Cabrera T
Tissue Antigens; 2010 Feb; 75(2):110-8. PubMed ID: 19912575
[TBL] [Abstract][Full Text] [Related]
32. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
[TBL] [Abstract][Full Text] [Related]
33. Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy.
Krüger T; Schoor O; Lemmel C; Kraemer B; Reichle C; Dengjel J; Weinschenk T; Müller M; Hennenlotter J; Stenzl A; Rammensee HG; Stevanović S
Cancer Immunol Immunother; 2005 Sep; 54(9):826-36. PubMed ID: 15627209
[TBL] [Abstract][Full Text] [Related]
34. Identification of an immunogenic CTL epitope of HIFPH3 for immunotherapy of renal cell carcinoma.
Sato E; Torigoe T; Hirohashi Y; Kitamura H; Tanaka T; Honma I; Asanuma H; Harada K; Takasu H; Masumori N; Ito N; Hasegawa T; Tsukamoto T; Sato N
Clin Cancer Res; 2008 Nov; 14(21):6916-23. PubMed ID: 18980986
[TBL] [Abstract][Full Text] [Related]
35. Immunomorphological characteristics of renal cell carcinoma.
Markovic-Lipkovski J; Brasanac D; Todorovic V; Müller CA; Müller GA
Histol Histopathol; 1995 Jul; 10(3):651-9. PubMed ID: 7579814
[TBL] [Abstract][Full Text] [Related]
36. Growth and major histocompatibility antigen expression regulation by IL-4, interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) on human renal cell carcinoma.
Hillman GG; Puri RK; Kukuruga MA; Pontes JE; Haas GP
Clin Exp Immunol; 1994 Jun; 96(3):476-83. PubMed ID: 8004818
[TBL] [Abstract][Full Text] [Related]
37. Altered pattern of major histocompatibility complex expression in renal carcinoma: tumor-specific expression of the nonclassical human leukocyte antigen-G molecule is restricted to clear cell carcinoma while up-regulation of other major histocompatibility complex antigens is primarily distributed in all subtypes of renal carcinoma.
Ibrahim EC; Allory Y; Commo F; Gattegno B; Callard P; Paul P
Am J Pathol; 2003 Feb; 162(2):501-8. PubMed ID: 12547708
[TBL] [Abstract][Full Text] [Related]
38. Prognostic markers for survival in patients with metastatic renal cell carcinoma treated with interleukin-2.
van Bezooijen RL; Goey H; Stoter G; Hermans J; Fleuren GJ
Cancer Immunol Immunother; 1996 Dec; 43(5):293-8. PubMed ID: 9024506
[TBL] [Abstract][Full Text] [Related]
39. Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7-1 (CD8O) costimulation.
Wang YC; Zhu L; McHugh R; Graham SD; Hillyer CD; Dillehay D; Sell KW; Selvaraj P
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):1-8. PubMed ID: 9147700
[TBL] [Abstract][Full Text] [Related]
40. [Expression of HLA class II antigen-associated invariant chain on renal cell cancer].
Saito T; Tomita Y; Kimura M; Nishiyama T; Sato S
Nihon Hinyokika Gakkai Zasshi; 1993 Jun; 84(6):1036-40. PubMed ID: 8345720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
